SAREUM HOLDINGS PLC

(“Sareum” or “the Company”)

HALF-YEARLY RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2012

Sareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce its half-yearly results for the six month period ended 31 December 2012.

Financial highlights

• Cash at bank at period end was £380,000 (2011: £530,000)
• £4M SEDA financing facility from YA Global Master SPV Ltd and  initial drawdown of £200,000
• Loss on ordinary activities (after taxation) of £269,000 (2011: Loss of £327,000)

Operational highlights

• Research and commercialisation of programmes making good progress
• Favourable ongoing safety studies with Chk1 pre-clinical development candidate
• US Patent grant notification for SKIL® compounds received post period in February 2013

Dr Tim Mitchell, CEO of Sareum Holdings plc, said: “We are pleased with progress and our confidence in our ability to exploit our research programmes commercially remains high. A key commercial goal remains to enter into profitable licensing arrangements but only when they represent a good return for shareholders. We continue to take in-house programmes forward by building more comprehensive pre-clinical dossiers and as appropriate moving forward into pre-clinical toxicology studies and ultimately Phase I clinical trials.”

The full report is avaialble as a pdf document: Financial Results for the Six Months Ended 31/12/12